Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:57 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 6,445 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Clear all
Completed Phase 4 Interventional Results available

Linagliptin's Effect on CD34+ Stem Cells

NCT02467478
View directory record Official record
Conditions
Type 2 Diabetes, Impaired Renal Function
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Nov 3, 2026, 2:57 AM EST
Completed Phase 4 Interventional Results available

BK Treatment Study

NCT01034176
View directory record Official record
Conditions
BK Viremia
Interventions
levofloxacin, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Nov 3, 2026, 2:57 AM EST
Completed Phase 1 Interventional

Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses

NCT02248389
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sonatherm 600i ablation system
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Nov 3, 2026, 2:57 AM EST
Completed Not applicable Interventional

Renal Denervation in Patients With Refractory Hypertension

NCT00753285
View directory record Official record
Conditions
Hypertension
Interventions
Renal Denervation
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Springfield, Illinois • Minneapolis, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Nov 3, 2026, 2:57 AM EST
Completed Not applicable Interventional

Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease

NCT01835691
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Vitamin D2 (ergocalciferol), Vitamin D3 (cholecalciferol)
Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Nov 3, 2026, 2:57 AM EST
Completed Phase 2Phase 3 Interventional Results available

To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

NCT05075408
View directory record Official record
Conditions
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
47
States / cities
Bakersfield, California • Glendale, California • La Palma, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 3, 2026, 2:57 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

Fernald Community Cohort -18 Year Observational Study

NCT02295085
View directory record Official record
Conditions
Cancer, Renal Failure, Diabetes, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
8 Years and older
Enrollment
9,782 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1990 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Nov 3, 2026, 2:57 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Peer-mentoring, Quality of Life and Caregiver Burden in Patients With Chronic Kidney Disease and Their Caregivers

NCT02429115
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Mentoring
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Harrisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Nov 3, 2026, 2:57 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance

NCT04074668
View directory record Official record
Conditions
Diabetic Kidney Disease, Type 1 Diabetes, Diabetes, Diabetes Mellitus, Diabetes Complications, Diabetic Nephropathies, Type1diabetes, Diabetes, Autoimmune, Autoimmune Diabetes, Juvenile Diabetes, Type 1 Diabetes Mellitus
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams/milliliter (mg/ml), PET/CT Scan, Renal Biopsy
Drug · Radiation · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Nov 3, 2026, 2:57 AM EST
Terminated Phase 3 Interventional Results available

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

NCT03315143
View directory record Official record
Conditions
Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
119
States / cities
Birmingham, Alabama • Sheffield, Alabama • Mesa, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Nov 3, 2026, 2:57 AM EST
Not listed Phase 3 Interventional

Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)

NCT04239391
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Loma Linda, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Nov 3, 2026, 2:57 AM EST
Terminated Phase 2 Interventional Results available

Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

NCT00429026
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
Fludarabine, Melphalan, Cyclophosphamide, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Nov 3, 2026, 2:57 AM EST
Completed Phase 3 Interventional

Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease

NCT00035308
View directory record Official record
Conditions
Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus, Lupus Nephritis, Lupus Glomerulonephritis
Interventions
Abetimus sodium (LJP 394)
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
12 Years to 70 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
66
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2006 · Synced Nov 3, 2026, 2:57 AM EST
Completed Phase 1Phase 2 Interventional Results available

CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00112840
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
CCI-779, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Nov 3, 2026, 2:57 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 3, 2026, 2:57 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease

NCT01341678
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lanthanum Carbonate, NeutraPhos, Diet Only
Drug · Dietary Supplement · Other
Lead sponsor
Geoffrey Block
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Nov 3, 2026, 2:57 AM EST
Recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

NCT06750185
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5, BNT317 DL6, BNT317 selected DLA, BNT317 selected DLB, SoC chemotherapy 1, SoC chemotherapy 2
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 3, 2026, 2:57 AM EST
Completed Phase 1 Interventional

Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia

NCT01057108
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Interventions
FOSTRAP Chewing Gum, Placebo chewing gum
Other
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Nov 3, 2026, 2:57 AM EST
Completed Phase 2 Interventional Results available

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

NCT01082640
View directory record Official record
Conditions
Renal Impairment
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
58
States / cities
Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Nov 3, 2026, 2:57 AM EST
Completed No phase listed Observational Accepts healthy volunteers

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™

NCT03095391
View directory record Official record
Conditions
Kidney Diseases, Renal Insufficiency, Chronic, Acute Kidney Injury, Urologic Diseases, Renal Insufficiency
Interventions
VFI, Iohexol
Device
Lead sponsor
FAST BioMedical
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Birmingham, Alabama • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Nov 3, 2026, 2:57 AM EST
Recruiting Phase 2 Interventional

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

NCT07085728
View directory record Official record
Conditions
Myeloma Multiple
Interventions
Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone, Daratumumab-hyaluronidase
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 3, 2026, 2:57 AM EST
Completed No phase listed Observational

Adipose Tissue Function After Pancreas Transplantation

NCT01729130
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions
Adipose tissue biopsy
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Nov 3, 2026, 2:57 AM EST
Withdrawn Phase 1Phase 2 Interventional

A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors

NCT01176500
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Cervical Cancer, Renal Cell Carcinoma, Uterine Cancer
Interventions
(18)Fluciclatide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 3, 2026, 2:57 AM EST
Recruiting Phase 1Phase 2 Interventional

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

NCT05508009
View directory record Official record
Conditions
SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
Interventions
Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant
Drug · Radiation · Device + 1 more
Lead sponsor
Alice Bertaina
Other
Eligibility
1 Year to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Nov 3, 2026, 2:57 AM EST